Current seasonal flu vaccines have ranged in effectiveness between 10% and 60% during the past 10 years, highlighting the innate variability in circulating flu strains from year to year. Imutex is leveraging technology licensed from SEEK to develop a Broad-Spectrum ‘Universal’ Influenza Vaccine (BIV), called FLU-v, against multiple flu strains. FLU-v works by targeting conserved internal proteins common to all flu viruses to activate T and B-cells, key components of the human immune system response. The success of such an approach would eliminate the sensitivity to strain variability seen with traditional vaccines and promote single vaccine coverage for all flu strains.
Working closely with the National Institute of Allergy and Infectious Disease in the United States (NIAID), Imutex leveraged the hVIVO and NIAID platforms to conduct Phase IIb clinical studies of FLU-v to evaluate the efficacy and safety of this novel vaccine. Both the field study and challenge study achieved the primary endpoints.
- Read more about the positive results from Phase IIb field study of FLU-v vaccine (FLU-v 003) here
- Read more about the positive results from FLU-v vaccine challenge study (FLU-v 004) here
Background information on Universal and Annual Flu vaccines can be found at www.endfluenza.com